138 related articles for article (PubMed ID: 24767861)
1. TNFAIP8 overexpression is associated with platinum resistance in epithelial ovarian cancers with optimal cytoreduction.
Liu T; Xia B; Lu Y; Xu Y; Lou G
Hum Pathol; 2014 Jun; 45(6):1251-7. PubMed ID: 24767861
[TBL] [Abstract][Full Text] [Related]
2. TNFAIP8 as a predictor of metastasis and a novel prognostic biomarker in patients with epithelial ovarian cancer.
Liu T; Gao H; Chen X; Lou G; Gu L; Yang M; Xia B; Yin H
Br J Cancer; 2013 Sep; 109(6):1685-92. PubMed ID: 23982604
[TBL] [Abstract][Full Text] [Related]
3. HPIP expression predicts chemoresistance and poor clinical outcomes in patients with epithelial ovarian cancer.
Wang Y; Li M; Meng F; Lou G
Hum Pathol; 2017 Feb; 60():114-120. PubMed ID: 27818289
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of TNFAIP8 is associated with tumor aggressiveness and poor prognosis in patients with invasive ductal breast carcinoma.
Xiao M; Xu Q; Lou C; Qin Y; Ning X; Liu T; Zhao X; Jia S; Huang Y
Hum Pathol; 2017 Apr; 62():40-49. PubMed ID: 28087477
[TBL] [Abstract][Full Text] [Related]
5. Upregulation of Abelson interactor protein 1 predicts tumor progression and poor outcome in epithelial ovarian cancer.
Zhang J; Tang L; Chen Y; Duan Z; Xiao L; Li W; Liu X; Shen L
Hum Pathol; 2015 Sep; 46(9):1331-40. PubMed ID: 26193797
[TBL] [Abstract][Full Text] [Related]
6. Expression of resistance gene and prognosis of chemotherapy in primary epithelial ovarian cancer.
Yang F; Gao B; Chen W; Du E; Liang Y; Hu X; Yang X
Medicine (Baltimore); 2018 Oct; 97(41):e12364. PubMed ID: 30313031
[TBL] [Abstract][Full Text] [Related]
7. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
8. Tumor necrosis factor α-induced protein 8 expression as a predictor of prognosis and resistance in patients with advanced ovarian cancer treated with neoadjuvant chemotherapy.
Wang J; Gao H; Liu G; Gu L; Yang C; Zhang F; Liu T
Hum Pathol; 2018 Dec; 82():239-248. PubMed ID: 30107189
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of YES1 is associated with favorable prognosis and increased platinum-sensitivity in patients with epithelial ovarian cancer.
Zhou Y; Chen P; Huang Q; Wan T; Jiang Y; Jiang S; Yan S; Zheng M
Histol Histopathol; 2020 Jul; 35(7):721-728. PubMed ID: 31970720
[TBL] [Abstract][Full Text] [Related]
10. TR3 modulates platinum resistance in ovarian cancer.
Wilson AJ; Liu AY; Roland J; Adebayo OB; Fletcher SA; Slaughter JC; Saskowski J; Crispens MA; Jones HW; James S; Fadare O; Khabele D
Cancer Res; 2013 Aug; 73(15):4758-69. PubMed ID: 23720056
[TBL] [Abstract][Full Text] [Related]
11. Platelet-Derived Growth Factor D Is a Prognostic Biomarker and Is Associated With Platinum Resistance in Epithelial Ovarian Cancer.
Zhang M; Liu T; Xia B; Yang C; Hou S; Xie W; Lou G
Int J Gynecol Cancer; 2018 Feb; 28(2):323-331. PubMed ID: 29240605
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of trophoblast cell surface antigen 2 as an independent marker for a poor prognosis and as a potential therapeutic target in epithelial ovarian carcinoma.
Xu N; Zhang Z; Zhu J; Xu L; Li Y; Duan L; Mao Y; Li H
Int J Exp Pathol; 2016 Apr; 97(2):150-8. PubMed ID: 27127000
[TBL] [Abstract][Full Text] [Related]
13. High claudin-7 expression is associated with a poor response to platinum-based chemotherapy in epithelial ovarian carcinoma.
Kim CJ; Lee JW; Choi JJ; Choi HY; Park YA; Jeon HK; Sung CO; Song SY; Lee YY; Choi CH; Kim TJ; Lee JH; Kim BG; Bae DS
Eur J Cancer; 2011 Apr; 47(6):918-25. PubMed ID: 21134740
[TBL] [Abstract][Full Text] [Related]
14. Expression of steroid receptor coactivator 3 in ovarian epithelial cancer is a poor prognostic factor and a marker for platinum resistance.
Palmieri C; Gojis O; Rudraraju B; Stamp-Vincent C; Wilson D; Langdon S; Gourley C; Faratian D
Br J Cancer; 2013 May; 108(10):2039-44. PubMed ID: 23652306
[TBL] [Abstract][Full Text] [Related]
15. Class III β-tubulin overexpression in ovarian clear cell and serous carcinoma as a maker for poor overall survival after platinum/taxane chemotherapy and sensitivity to patupilone.
Roque DM; Bellone S; Buza N; Romani C; Cocco E; Bignotti E; Ravaggi A; Rutherford TJ; Schwartz PE; Pecorelli S; Santin AD
Am J Obstet Gynecol; 2013 Jul; 209(1):62.e1-9. PubMed ID: 23583215
[TBL] [Abstract][Full Text] [Related]
16. TNFAIP8 overexpression: a potential predictor of lymphatic metastatic recurrence in pN0 esophageal squamous cell carcinoma after Ivor Lewis esophagectomy.
Sun Z; Liu X; Song JH; Cheng Y; Liu Y; Jia Y; Meltzer SJ; Wang Z
Tumour Biol; 2016 Aug; 37(8):10923-34. PubMed ID: 26886285
[TBL] [Abstract][Full Text] [Related]
17. RUNX3 contributes to carboplatin resistance in epithelial ovarian cancer cells.
Barghout SH; Zepeda N; Vincent K; Azad AK; Xu Z; Yang C; Steed H; Postovit LM; Fu Y
Gynecol Oncol; 2015 Sep; 138(3):647-55. PubMed ID: 26186909
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of CHI3L1 is associated with chemoresistance and poor outcome of epithelial ovarian carcinoma.
Chiang YC; Lin HW; Chang CF; Chang MC; Fu CF; Chen TC; Hsieh SF; Chen CA; Cheng WF
Oncotarget; 2015 Nov; 6(37):39740-55. PubMed ID: 26452028
[TBL] [Abstract][Full Text] [Related]
19. Survivin status affects prognosis and chemosensitivity in epithelial ovarian cancer.
Chen L; Liang L; Yan X; Liu N; Gong L; Pan S; Lin F; Zhang Q; Zhao H; Zheng F
Int J Gynecol Cancer; 2013 Feb; 23(2):256-63. PubMed ID: 23358177
[TBL] [Abstract][Full Text] [Related]
20. DcR3 binds to ovarian cancer via heparan sulfate proteoglycans and modulates tumor cells response to platinum with corresponding alteration in the expression of BRCA1.
Connor JP; Felder M; Kapur A; Onujiogu N
BMC Cancer; 2012 May; 12():176. PubMed ID: 22583667
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]